ACR Convergence 2025| Video: Rheum for Everyone, Episode 26—Ableism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: pediatric

Government Affairs: A Marathon, Not a Sprint

Donald Miller, PharmD  |  June 10, 2024

Government Affairs Committee member Donald Miller, PharmD, reflects on the effects of rheumatology advocacy work over time, noting that progress is often easier to see from the distance.

Filed under:Legislation & Advocacy Tagged with:ACR advocacyGovernment Affairs Committee (GAC)

When Rheumatologists Have Rheumatic Diseases

Jason Liebowitz, MD, FACR  |  June 10, 2024

  “I think we learn from medicine everywhere that it is, at its heart, a human endeavor, requiring good science but also a limitless curiosity and interest in your fellow human being, and that the physician-patient relationship is key; all else follows from it.”1 These profound words from Abraham Verghese, MD, MACP, Linda R. Meier…

Filed under:CareerPatient PerspectiveProfiles Tagged with:Empathypatient-clinician relationshipphysician patient relationship

FDA Approves Tocilizumab Biosimilar; Plus New Lupus Drug in Early Trials

Michele B. Kaufman, PharmD, BCGP  |  May 30, 2024

The FDA has approved tocilizumab-aazg (Tyenne), the first tocilizumab biosimilar, for treating rheumatic diseases, as well as the new drug application for CB-101, a chimeric antigen receptor T cell therapy, for treating lupus nephritis and extra-renal lupus.

Filed under:Biologics/DMARDsDrug UpdatesPediatric ConditionsRheumatoid ArthritisSystemic Lupus ErythematosusVasculitis Tagged with:FDAtocilizumabtocilizumab-aazgU.S. Food and Drug Administration (FDA)

How to Effectively Diagnose & Treat Macrophage Activation Syndrome

Vanessa Caceres  |  May 30, 2024

“As a resident, [I] felt pretty terrible when [we had] a very sick child and the teams [couldn’t] agree on what to do,” said Lauren Henderson, MD, MMS, on an episode of ACR on Air. She discussed the importance of collaboration across specialties in the identification and treatment of macrophage activation syndrome (MAS).

Filed under:ConditionsPediatric ConditionsVasculitis Tagged with:hemophagocytic lymphohistiocytosis (HLH)macrophage activation syndromeMASpatient care

ACR Delegation to Lead Several Resolutions at June AMA House of Delegates Meeting

From the College  |  May 21, 2024

The ACR will lead five other specialty societies on a resolution supporting pediatric specialty care and will co-lead resolutions addressing Medicare Advantage Part B drug coverage, white bagging mandates, state prescription drug affordability boards and impacts of alternative funding programs on access to care.

Filed under:American College of RheumatologyLegislation & AdvocacyPractice Support Tagged with:ACR advocacyAMA House of Delegates (HOD)

Insurance Denial Woes? The ACR Can Help with Appeal Letter Templates

From the College  |  May 16, 2024

Don’t reinvent the wheel. The ACR Committee on Rheumatologic Care offers members an updated slate of template letters to help appeal insurance denials for common off-label rheumatology treatments.

Filed under:InsurancePractice Support Tagged with:insurance denialsoff-label use

Case Report: Complicated Presentation Eventually Explained by Rare Syndrome

Geoffrey E. Thiele, MD, & Iris Reyhan, MD  |  April 10, 2024

Pachydermoperiostosis (PDP), also known as Touraine-Solente-Golé syndrome or primary hypertrophic osteoarthropathy, is a rare syndrome that can be inherited as autosomal dominant, autosomal recessive, or sporadically. This progressive disease primarily affects males, who tend to have more severe features than females. PDP usually occurs during adolescence, often starting around puberty.1 The main clinical features are…

Filed under:ConditionsOther Rheumatic Conditions Tagged with:case reportCrohn's diseasePachydermoperiostosisprimary hypertrophic osteoarthropathyTouraine-Solente- Golé syndrome

The Biases We Don’t Know We Hold

Vanessa Caceres  |  March 26, 2024

Implicit bias can affect patient care at the physician level when they’re making treatment decisions and at the healthcare organization level when they’re choosing new hires. Here are insights into strategies rheumatologists can use to become aware of, and question, their implicit biases.

Filed under:OpinionPractice SupportWorkforce Tagged with:biasdiscriminationEquityinclusion

Mental Health in Rheumatology

Vanessa Caceres  |  March 26, 2024

Regaining a sense of control, limiting responsibilities and engaging in mindfulness can help rheumatologists manage their mental health needs. Rheumatologists should also address the mental health concerns raised by their patients. Here are insights from a psychiatrist/rheumatologist.

Filed under:ConditionsOther Rheumatic Conditions Tagged with:burnoutMental Health

When to Check Drug Levels & Why

Stephen J. Balevic, MD, PhD, RhMSUS  |  March 7, 2024

Checking blood levels of commonly used disease-modifying anti-rheumatic drugs (DMARDs) has gained widespread attention in the rheumatology community, even resulting in a recent guidance document from EULAR for biologics.1 Although a highly useful tool, drug level measurement in rheumatology is not without challenges; many of our drugs violate the basic principles of pharmacology that we…

Filed under:Biologics/DMARDsConditionsDrug UpdatesRheumatoid ArthritisSystemic Lupus Erythematosus Tagged with:adalimumabadherenceazathioprinedosagedosage adjustmentdrug levelsetanerceptHYDROXYCHLOROQUINEinfliximabmycophenoloateSLE Resource Centertherapeutic drug monitoring

  • « Previous Page
  • 1
  • …
  • 21
  • 22
  • 23
  • 24
  • 25
  • …
  • 112
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences